Get the Stockscreener App
181.80
1.65%
-3.05
After Hours:
181.30
-0.50
-0.28%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $181.80, with a volume of 4.82M.
It is down -1.65% in the last 24 hours and up +6.84% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$184.85
Open:
$183.93
24h Volume:
4.82M
Relative Volume:
0.63
Market Cap:
$321.13B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
77.36
EPS:
2.35
Net Cash Flow:
$15.39B
1W Performance:
+2.46%
1M Performance:
+6.84%
6M Performance:
+5.86%
1Y Performance:
+11.58%
1-Day Range:
$181.54
$184.81
1-Week Range:
$176.57
$186.00
52-Week Range:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
181.80 | 313.43B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
724.95 | 642.38B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.18 | 352.15B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVS
Novartis Ag Adr
|
112.78 | 207.36B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
68.20 | 286.20B | 43.59B | 15.04B | 10.74B | 3.3766 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Gets Victory In Allergan Shareholder Suit Upheld - Law360
Court upholds dismissal of AbbVie-Allergan merger suit - Crain's Chicago Business
AbbVie, Allergan Merger Suit Dismissal Upheld By Illinois Court - Bloomberg Law News
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView
Cancer Cachexia Market Detailed in New Research Report By 2032 | AbbVie Inc., Actimed Therapeutics - openPR.com
Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail
Plastic Surgery Market Fly Massive Growth in Years to Come: AbbVie, Johnson & Johnson Services, Sientra - openPR.com
AbbVie Hits Last Generic-Orilissa Holdout With New Patent Suit - Bloomberg Law News
Ameriprise Financial Initiates AbbVie at Buy - marketscreener.com
AbbVie (ABBV) Soared on Favorable Tailwinds - Insider Monkey
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class ActionABBV - Morningstar
Former AbbVie, Takeda omnichannel lead Dan Gandor joins Eversana Intouch - Medical Marketing and Media
Cerevel Therapeutics Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class ActionABBV - marketscreener.com
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie - TradingView
Perion, Sea, KKR, Chimera, AbbVie: Trending by Analysts - TipRanks
Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock” - MSN
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear - simplywall.st
Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings - Yahoo Finance
3 Stocks That Will Profit From Trump's Drug Price CutAbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN) - Benzinga
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - TradingView
7th Circ. Weighs AbbVie Whistleblower's Drug Marketing Suit - Law360
AbbVie’s Solid Tumor Strategy Gets a Win With Accelerated FDA Approval in Lung Cancer - MedCity News
FDA awards cancer drug approvals to AbbVie and MSD - Yahoo Finance
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV - TradingView
AbbVie stakes $335M on a startup’s RNAi drugs - BioPharma Dive
FDA Approves AbbVie’s Emrelis - The Pharma Letter
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025 - Benzinga
AbbVie & ADARx Partner on Next-Gen siRNA Therapeutics - Contract Pharma
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - Yahoo Finance
Psoriasis Drugs Market Set to Witness Significant Growth by 2033 - openPR.com
AbbVie and ADARx Pharmaceuticals Announce Collaboration - citybiz
AbbVie bags first approval for cancer ADC Emrelis - Pharmaphorum
AbbVie expands siRNA push with $335m ADARx deal - Yahoo Finance
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com
AbbVie Emrelis gets USFDA accelerated approval for a type of lung cancer - Medical Dialogues
Regeneron Upgraded as AbbVie Catches Policy Heat - GuruFocus
Buy Rating for AbbVie’s Emrelis Supported by FDA Approval and Promising NSCLC Treatment Potential - TipRanks
US FDA approves AbbVie's drug for a type of lung cancer - Reuters
AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics - insights.citeline.com
Yes siRNA: Adarx/Abbvie tie-up worth “several billion” dollars - BioWorld MedTech
AbbVie On MFN: ‘We Have To Take It Seriously’ - insights.citeline.com
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer (NYSE:ABBV) - Seeking Alpha
US FDA approves AbbVie’s drug for a type of lung cancer - 1470 & 100.3 WMBD
AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies - Dermatology Times
US FDA clears Abbvie’s c-Met lung cancer ADC - BioWorld MedTech
FDA Grants Accelerated Approval to AbbVie's Emrelis for Lung Can - GuruFocus
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases - Yahoo Finance
Transcript : AbbVie Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
AbbVie (ABBV) Gains FDA Accelerated Approval for Emrelis | ABBV Stock News - GuruFocus
AbbVie wins approval of Emrelis for non-small cell lung cancer - Seeking Alpha
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):